Advanced search
Publication Cover
Future Cardiology Volume 11, 2015 - Issue 4
Submit an article Journal homepage
1,785
Views
1
CrossRef citations to date
0
Altmetric
Editorial

Managing anthracycline-induced Cardiotoxicity: Beginning With the End in Mind

Emanuela Salvatorelli1 Unit of Drug Sciences Department of Medicine University Campus Bio-Medico Via Alvaro del Portillo 21Rome00128ItalyView further author information
,
Pierantonio Menna1 Unit of Drug Sciences Department of Medicine University Campus Bio-Medico Via Alvaro del Portillo 21Rome00128Italy;2 Unit of Clinical Pharmacology Campus Bio-Medico University Hospital Via Alvaro del Portillo 200Rome00128ItalyView further author information
&
Giorgio Minotti1 Unit of Drug Sciences Department of Medicine University Campus Bio-Medico Via Alvaro del Portillo 21Rome00128Italy;2 Unit of Clinical Pharmacology Campus Bio-Medico University Hospital Via Alvaro del Portillo 200Rome00128ItalyCorrespondence[email protected]
View further author information
Pages 363-366 | Published online: 04 Aug 2015

References

  • Swain SM , WhaleyFS, EwerMS . Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials . Cancer97 ( 11 ), 2869 – 2879 ( 2003 ).
  • Minotti G , SalvatorelliE, MennaP . Pharmacological foundations of Cardio-Oncology . J. Pharmacol. Exp. Ther.334 ( 1 ), 2 – 8 ( 2010 ).
  • Swerdlow AJ , HigginsCD, SmithPet al. Myocardial infarction mortality risk after treatment for Hodgkin disease: A collaborative British Cohort Study . J. Natl Cancer. Inst.99 ( 3 ), 206 – 214 ( 2007 ).
  • Yeh ET , SalvatorelliE, MennaP, MinottiG . What is cardiotoxicity?Progr. Pediatr. Cardiol.36 ( 1–2 ), 3 – 6 ( 2014 ).
  • Von Hoff DD , LayardMW, BasaPet al. Risk factors for doxorubicin-induced congestive heart failure . Ann. Intern. Med.91 ( 5 ), 710 – 717 ( 1979 ).
  • Salvatorelli E , MennaP, CantalupoEet al. The concomitant management of cancer therapy and cardiac therapy . Biochim. Biophys. Acta doi:10.1016/j.bbamem.2015.01.003 ( 2015 ) ( Epub ahead of print ).
  • Minotti G , MennaP, SalvatorelliE, CairoG, GianniL . Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity . Pharmacol. Rev.56 ( 2 ), 185 – 229 ( 2004 ).
  • Lipshultz SE , MillerTL, LipsitzSRet al. Continuous versus bolus infusion of doxorubicin in children with ALL: long-term cardiac outcomes . Pediatrics130 ( 6 ), 1003 – 1011 ( 2012 ).
  • Menna P , Gonzalez PazO, ChelloMet al. Anthracycline cardiotoxicity . Expert. Opin. Drug. Saf.11 ( Suppl. 1 ), S21 – S36 ( 2012 ).
  • Swain SM , WhaleyFS, GerberMCet al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer . J. Clin. Oncol.15 ( 4 ), 1318 – 1332 ( 1997 ).
  • Tebbi CK , LondonWB, FriedmanDet al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease . J. Clin. Oncol.25 ( 5 ), 493 – 500 ( 2007 ).
  • Lipshultz SE , FrancoVI, SallanSEet al. Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: an update of the evidence . Progr. Pediatr. Cardiol.36 ( 1–2 ), 39 – 49 ( 2014 ).
  • Wouters KA , KremerLC, MillerTLet al. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies . Br. J. Haematol.131 ( 5 ), 561 – 578 ( 2005 ).
  • Cardinale D , ColomboA, SandriMTet al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition . Circulation114 ( 23 ), 2474 – 2481 ( 2006 ).
  • Minotti G . Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs . J. Pharmacol. Exp. Ther.346 ( 3 ), 343 – 349 ( 2013 ).
  • Vejpongsa P , YehETH . Prevention of anthracycline-induced cardiotoxicityJ. Am. Coll. Cardiol.64 ( 9 ), 938 – 945 ( 2014 ).
  • Menna P , SalvatorelliE, MinottiG . Cardiotoxicity of antitumor drugs . Chem. Res. Toxicol.15 ( 9 ), 1179 – 1189 ( 2008 ).
  • Nathan PC , FordJS, HendersonTOet al. Health behaviors, medical care, and interventions to promote healthy living in the Childhood Cancer Survivor Study cohort . J. Clin. Oncol.27 ( 14 ), 2363 – 2373 ( 2009 ).
  • Jones SE , HolmesFA, O’ShaughnessyJAet al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7 year follow-up of US Oncology Research Trial 9735 . J. Clin. Oncol.27 ( 8 ), 1177 – 1183 ( 2009 ).
  • Gianni L , ValagussaP . Anthracyclines and early breast cancer: the end of an era?J. Clin. Oncol.27 ( 8 ), 1155 – 1157 ( 2009 ).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.